In early reports, curcumin was shown to inhibit the STAT5 signaling pathway in primary CML cells, highlighting its ability to interfere with BCR-ABL downstream signaling cascades [134]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.